Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study

This article has no abstract
Epistemonikos ID: 804e19d48127bebfee5bca007685bbeb76075c94
First added on: Feb 05, 2025